Evaro
Evaro is a UK-based, NHS-licensed digital health platform that provides API-first white-label clinical infrastructure — consultations, e-prescribing, dispensing, and delivery — to consumer brands and healthcare companies. It serves 2M+ patients across 80+ conditions through partners including Clue, Lovehoney, and Patchs.
- Company typePrivate
- Founded2018
- HeadquartersNorwich, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Evaro does
Evaro (legal entity: Total Access Health Ltd.) is a UK-based, Norwich-headquartered digital health infrastructure company founded in 2018 by NHS doctors and pharmacists Dr Thuria Wenbar (CEO) and Dr Oskar Wenbar (COO). The company operates an API-first, white-label platform that enables consumer brands, healthcare companies, and digital health platforms to embed regulated clinical services — asynchronous AI-assisted consultations, e-prescribing, pharmacy dispensing, and next-day delivery — directly into their own products under their own brand. Evaro holds the full stack of UK clinical and pharmaceutical licences required to deliver these services at scale, including GPhC pharmacy registration, CQC provider registration, MHRA registered pharmacy status, controlled drugs, specials manufacturing, and wholesale dealer licences, plus ISO 27001 and GDPR compliance and NHS Partner status for services such as oral contraception and Pharmacy First.
Evaro generates revenue through three primary streams: per-prescription transaction fees, recurring B2B platform/licensing fees for white-label and bespoke integration partners, and commission/revenue-share arrangements with pharmacy and delivery partners. Pricing for patient consultations is free at the point of use through partner platforms, while B2B partnership pricing is quote-based and not publicly disclosed. The company distributes exclusively through B2B partnerships, with no direct-to-consumer storefront, and serves a disclosed partner portfolio that includes Clue, Lovehoney, Patchs, e-Surgery, e-Pharmacy, Diabetes Consults, and U-Test Diagnostics across femtech, retail, digital health, online pharmacy, specialty care, and diagnostics.
The platform covers 80+ conditions with 500+ treatments, completes asynchronous consultations in approximately two minutes, delivers medications within 24 hours nationwide across England, Scotland, and Wales, and has cumulatively supported more than 2 million patients. Evaro has raised $26.5M in venture funding to date — a $1.5M seed led by Cornerstone VC and Exceptional Ventures (Jan 2024) and a $25M Series A led by AlbionVC with Simplyhealth Ventures (Jan 2026) — and currently operates with 100–150 employees. The Series A use of funds targets expansion into women's health, men's health, and longevity medicine with a stated goal of 10 million patients within three years.
Evaro firmographics
Firmographics- Name
- Evaro
- Legal name
- Total Access Health Ltd.
- Website
- https://evaro.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Evaro is a UK-based, NHS-licensed digital health platform that provides API-first white-label clinical infrastructure — consultations, e-prescribing, dispensing, and delivery — to consumer brands and healthcare companies. It serves 2M+ patients across 80+ conditions through partners including Clue, Lovehoney, and Patchs.
- Ownership category
- akta.pro rank
Evaro industry classification
Industry- Product category
- Digital Health Platform
- NAICS
- Software Publishers (513210), Offices of Physicians (6211), Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372), Services-Offices & Clinics Of Doctors Of Medicine (8011), Retail-Drug Stores And Proprietary Stores (5912)
- akta.pro primary industry
- DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)
- akta.pro secondary industry
- ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history) (HLALAIAD)
Keywords
Where Evaro is headquartered
LocationHeadquarters
- HQ city
- Norwich
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Evaro business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Prescription Fees: Revenue generated from prescription services, likely per-consultation or per-prescription fees charged to patients or passed through from pharmacy fulfillment
- B2B Platform/Licensing Fees: White-label partnership model where healthcare brands and consumer platforms pay for access to Evaro's NHS-licensed clinical infrastructure
- Partner Commissions: Commission or revenue share arrangements with pharmacy partners and delivery services integrated into the platform
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Patient Consultations |
| Unit Pricing | Pay-as-you-go | Delivery Services |
| Subscription | Annual | B2B Platform Licensing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Evaro product offering
Product offeringCore offering
Evaro operates an API-first digital healthcare platform that enables consumer brands, healthcare companies, and digital health platforms to embed NHS-licensed prescription and consultation services into their own platforms via white-label partnerships. The platform manages the complete prescription lifecycle, including AI-assisted 2-minute online consultations, in-house clinician prescribing, pharmacy dispensing, 24-hour nationwide delivery, and ongoing aftercare across 80+ conditions and 500+ treatments.
Product overview
Evaro operates as a unified digital healthcare platform with an API-first architecture. The core Evaro Platform serves as the foundational infrastructure, supplemented by the e-Surgery sub-brand for direct patient services. The company offers three integration tiers through its Healthcare-as-a-Service model: the forthcoming Self Service Portal (for small businesses), White Label Partnership (full rebrand option), and Platform Integration (bespoke enterprise solution). The platform handles the complete prescription lifecycle from 2-minute AI-assisted consultations through prescribing, pharmacy fulfillment, 24-hour delivery, and ongoing aftercare, supporting over 80 conditions with more than 500 treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- Evaro Platform API-first digital healthcare platform enabling consumer brands and healthcare companies to embed regulated clinical services including AI-driven consultations, e-prescribing, and pharmacy fulfilment. Supports 80+ conditions with 500+ treatments. Targeted at B2B partners.
- Healthcare-as-a-Service Model
Quantifiable outcome
- 2-minute consultation completion time
- +4 more outcomes
Companies that use Evaro
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
Evaro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability3 records
Feature3 records
Evaro partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered flagship and core.
- ClueflagshipPeriod tracking app partnership for NHS contraception services - embedding Evaro's prescription services into Clue's femtech platform to provide contraceptive consultations and prescriptions to users
- LovehoneyflagshipSexual wellness retailer partnership - embedding prescription services into Lovehoney's e-commerce platform for sexual health products and consultations
- PatchscoreDigital health platform partnership integrating consultation and prescription services
- e-SurgerycoreOnline pharmacy partnership providing prescription service integration for digital pharmacy services
- e-PharmacycoreDigital pharmacy partnership for prescription and consultation services integration
- Diabetes ConsultscoreSpecialty healthcare partnership providing diabetes consultation and prescription pathways
- U-Test DiagnosticscoreEnd-to-end diagnostic to prescription pathway partnership - connecting diagnostic testing services with prescription fulfillment through Evaro's platform
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Evaro competitors and assessment
Company assessmentDirect peers
- Zava: UK-based online doctor and pharmacy service offering asynchronous consultations and prescription fulfilment across a wide range of conditions. Most direct peer to Evaro given overlapping UK DTC telehealth + pharmacy model and comparable regulatory footprint.
- Superdrug Online Doctor: UK high-street retailer's telehealth and online pharmacy platform offering consultation-driven prescriptions. Comparable patient flow, condition range, and pharmacy integration to e-Surgery.
- LloydsPharmacy Online Doctor: Online consultation and prescription service from one of the UK's largest pharmacy chains. Direct competitor in DTC prescription telehealth with similar treatment catalogue and delivery proposition.
- Simple Online Pharmacy: UK GPhC-registered online pharmacy offering asynchronous consultations, ePrescribing, and home delivery across a broad condition set. Direct comparable in scale, regulatory profile, and patient experience.
- Pharmacy2U: Largest NHS-registered online pharmacy in the UK offering NHS and private prescriptions with home delivery. Direct peer in UK online pharmacy and ePrescribing infrastructure, including NHS repeat prescribing.
Broad incumbents
- Boots Online Doctor: Boots' online consultation and prescription service covering weight loss, contraception, hair loss and other conditions. Broader incumbent with pharmacy retail footprint but overlapping core telehealth and ePrescribing proposition.
- Babylon Health (eMed): Originally a UK telehealth pioneer, now part of eMed. Provides asynchronous and synchronous consultations, prescribing, and pharmacy partnerships across multiple conditions. Comparable regulatory and clinical infrastructure but operates at much larger scale.
- Hims & Hers Health: US-listed D2C telehealth and pharmacy platform operating its own consumer brands across weight loss, hair, skin, mental and sexual health. Useful international comparable for Evaro's planned expansion across women's, men's and longevity medicine verticals.
Emerging players
- Truepill: US-based white-label telehealth and pharmacy infrastructure provider powering D2C health brands. Closest international analogue to Evaro's API-first, embeddable healthcare-as-a-service model for consumer brands.
Regional players
- AccuRx: UK healthcare software platform embedded into GP and primary care workflows. Comparable in embedding NHS-licensed infrastructure into partner systems, but focused on clinician-to-patient messaging rather than prescription telehealth.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Evaro social profiles
Digital presenceEvaro compliance and trust
Trust signalCompliance12 records
Evaro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Evaro leadership team
Management profileNumber of profiles
Profiles5 records
Evaro subsidiaries and ownership
Company hierarchySubsidiaries1 record
Evaro funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Evaro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Evaro
What does Evaro do?
Evaro operates an API-first digital healthcare platform that enables consumer brands, healthcare companies, and digital health platforms to embed NHS-licensed prescription and consultation services into their own platforms via white-label partnerships. The platform manages the complete prescription lifecycle, including AI-assisted 2-minute online consultations, in-house clinician prescribing, pharmacy dispensing, 24-hour nationwide delivery, and ongoing aftercare across 80+ conditions and 500+ treatments.
Is Evaro a public or private company?
Evaro is a private company. It is classified as venture growth investor backed and is currently operating.
When was Evaro founded?
Evaro was founded in 2018. It employs 11 to 50 people.
Where is Evaro based?
Evaro is headquartered in Norwich, United Kingdom, in the Europe region.
How does Evaro make money?
Three revenue lines are on record. Prescription Fees are the primary driver. The others are B2B Platform/Licensing Fees and partner Commissions.
Who are Evaro's main competitors?
Direct peers on record are Zava, Superdrug Online Doctor, LloydsPharmacy Online Doctor, Simple Online Pharmacy and Pharmacy2U. Broad incumbents are Boots Online Doctor, Babylon Health (eMed) and Hims & Hers Health. Truepill is listed as an emerging player. AccuRx is listed as a regional player.
Does Evaro have an API?
No public API is recorded for Evaro.
What industry is Evaro in?
Evaro's product category is Digital Health Platform. Its primary akta.pro industry code is HLALAIAA, DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription), with a secondary code of HLALAIAD, ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history). Its NAICS code is 513210 and its SIC code is 7372.